Progress Pulse

Short summaries of scientific findings from across the St. Jude research enterprise.

Targeting oncofetal tenascin C with immunotherapy requires a signal boost

Adding activation signals improves solid and brain tumor immunotherapy.

Model facilitates research on the second most common form of sickle cell disease

o Explore new models of HbSC, which recapitulate the disease’s human symptoms and other pathologies, created by St. Jude research to find better treatments.